Novocure (NVCR) Appoints Kristin Stafford to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Nasdaq lags on angst over AI spending ahead of earnings reports
Kristin Stafford Joins Novocure Board of Directors
March 29, 2023 7:30 AM EDTROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocures Board of Directors.
We look forward to welcoming Ms. Stafford to our board of directors, said William Doyle, Novocures Executive Chairman. Her broad expertise in finance in the life sciences sector and experience with a leading funder of innovation across the biopharmaceutical industry will be valuable as our global organization prepares for future growth.
Ms. Stafford is Senior Vice President, Chief Accounting Officer for Royalty Pharma plc, a position she has held since December... More
